Eli Lilly and Company: Attention Deficit Disorder with Hyperactivity trials

The registry lists 53 Attention Deficit Disorder with Hyperactivity studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 27 have results posted.

Phase 1 1Phase 2 6Phase 3 24Phase 4 23No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Bioequivalence (BE) Study in Healthy SubjectsCompletedNCT01177943Phase 1Results posted
• A Study in Attention Deficit Hyperactivity Disorder in Children and AdolescentsTerminatedNCT01127646Phase 4Results posted
• A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity DisorderCompletedNCT00969618Phase 3Results posted
• A Study of Pediatric Participants With Attention Deficit/Hyperactivity DisorderTerminatedNCT00965419Phase 2/3Results posted
• Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity DisorderCompletedNCT00962104Phase 3Results posted
• A Study of Pediatric Patients With Attention Deficit/Hyperactivity DisorderCompletedNCT00922636Phase 2/3Results posted
• Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)CompletedNCT00760747Phase 4Results posted
• Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid DyslexiaCompletedNCT00716274Phase 4Results posted
• A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00700427Phase 3Results posted
• Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusETerminatedNCT00687609Phase 4Results posted
• Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00636818Phase 2Results posted
• Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid DyslexiaCompletedNCT00607919Phase 4Results posted
• Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00568685Phase 3Results posted
• Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00546910Phase 4Results posted
• Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00530335Phase 2Results posted
• Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesCompletedNCT00510276Phase 4Results posted
• A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With AtomoxetineCompletedNCT00471354Phase 4Results posted
• A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and AdolescentsCompletedNCT00447278Phase 3Results posted
• Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in GermanyCompletedNCT00406354Phase 4Results posted
• Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum DisorderCompletedNCT00380692Phase 4Results posted
• Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00320528Phase 3Results posted
• An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).CompletedNCT00192023Phase 3Results posted
• Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00191945Phase 3Results posted
• Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)CompletedNCT00191906Phase 4Results posted
• Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)CompletedNCT00191386Phase 3Results posted
• A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00190775Phase 4Results posted
• Long-Term, Open Label Atomoxetine StudyCompletedNCT00190684Phase 3Results posted
• Safety Study of Atomoxetine and Cerebrovascular OutcomesCompletedNCT00634439
• Treatment Compliance in Children and Adolescents on ADHD MedicationCompletedNCT00540826
• Evaluation of Continuous Symptom Treatment of ADHDCompletedNCT00486122Phase 4
• Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHDCompletedNCT00486083Phase 3
• Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHDCompletedNCT00485875Phase 4
• A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASDCompletedNCT00485849Phase 4
• Safety Study in Outpatient Japanese Children With ADHDCompletedNCT00485628Phase 2
• Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant TherapyCompletedNCT00485550Phase 3
• Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHDCompletedNCT00485459Phase 3
• Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of AtomoxetineCompletedNCT00485407Phase 3
• Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity DisorderCompletedNCT00386581Phase 3
• Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.CompletedNCT00216918Phase 4
• Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity DisorderCompletedNCT00191880Phase 3
• An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity DisorderCompletedNCT00191737Phase 3
• Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODDCompletedNCT00191698Phase 3
• Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/AdolescentsCompletedNCT00191659Phase 3
• Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional OutcomesCompletedNCT00191633Phase 4
• Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and AdolescentsCompletedNCT00191542Phase 3
• An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity DisorderCompletedNCT00191516Phase 3
• Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00191295Phase 2/3
• Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHDCompletedNCT00191048Phase 4
• Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHDCompletedNCT00191035Phase 4
• Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol AbuseCompletedNCT00190957Phase 4
• A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity DisorderCompletedNCT00190931Phase 4
• Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety DisorderCompletedNCT00190879Phase 4
• Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)CompletedNCT00190736Phase 4